Original language | English (US) |
---|---|
Pages (from-to) | E71-E74 |
Journal | American journal of hematology |
Volume | 96 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2021 |
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American journal of hematology, Vol. 96, No. 3, 01.03.2021, p. E71-E74.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults
T2 - association with CRLF2 rearrangement and poor prognosis
AU - Koller, Paul B.
AU - Zhang, Hui
AU - Kantarjian, Hagop
AU - Jabbour, Elias
AU - Pierce, Sherry
AU - Gocho, Yoshihiro
AU - Roberts, Kathryn G.
AU - Yang, Wenjian
AU - Mullighan, Charles G.
AU - Yang, Jun
AU - Konopleva, Marina
AU - Jain, Nitin
N1 - Funding Information: Paul Koller: Consulting Fees: Jazz. Hagop Kantarjian: Research Grants: AbbVie, Amgen, Ascentage, BMS, Daiichi‐Sankyo, Immunogen, Jazz, Novartis, Pfizer, Sanofi. Honoraria: AbbVie, Actinium (Advisory Board), Adaptive Biotechnologies, Amgen, Apptitude Health, BioAscend, Daiichi‐Sankyo, Delta Fly, Janssen Global, Novartis, Oxford Biometical, Pfizer, Takeda. Elias Jabbour: research grants and consultancy fees from Abbvie, Adaptive Biotechnologies, Amgen, BMS, Genentech, Pfizer and Takeda. Charles Mullighan: Research funding: Loxo Oncology, Pfizer, Abbvie. Speaking: Amgen, SAB: Illumina. Marina Konopleva: Grant support and consulting fees from AbbVie, Genentech, F. Hoffmann La‐Roche, Stemline Therapeutics, Forty‐Seven, consulting fees from Amgen and Kisoji, grant support from Eli Lilly, Cellectis, Calithera, Ablynx, Agios, Ascentage, AstraZeneca, Rafael Pharmaceutical, Sanofi, royalties and stock options from Reata Pharmaceutical Inc., and patent US 7795305 B2 on CDDO‐compounds and combination therapies, licensed to Reata Pharmaceutical. Nitin Jain: Research Funding: Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Aprea Therapeutics Advisory Board/Honoraria: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies, Servier, Precision Biosciences, TG Therapeutics, Beigene.
PY - 2021/3/1
Y1 - 2021/3/1
UR - http://www.scopus.com/inward/record.url?scp=85099502294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099502294&partnerID=8YFLogxK
U2 - 10.1002/ajh.26065
DO - 10.1002/ajh.26065
M3 - Letter
C2 - 33275800
AN - SCOPUS:85099502294
SN - 0361-8609
VL - 96
SP - E71-E74
JO - American journal of hematology
JF - American journal of hematology
IS - 3
ER -